THE New Development Bank (NDB) of the BRICS bloc has put all new transactions in Russia on hold citing the "unfolding uncertainties and restrictions", amidst the Ukraine crisis.
The NDB's move came a day after the Asian Infrastructure Investment Bank (AIIB) put on hold all its projects in Russia and its ally Belarus.
“The New Development Bank (NDB) applies sound banking principles in all its operations, as stated in its Articles of Agreement”, a statement by the bank posted on its website on Thursday (3) said.
“In light of unfolding uncertainties and restrictions, NDB has put new transactions in Russia on hold”, it said.
“NDB will continue to conduct business in full conformity with the highest compliance standards as an international institution,” it said.
The NDB was established by Brazil, Russia, India, China and South Africa (BRICS) to mobilise resources for infrastructure and sustainable development projects in BRICS and other emerging economies and developing countries.
On Thursday (3), the China-based AIIB put on hold all its projects in Russia and its ally Belarus.
The bank's decision was regarded as noteworthy considering that Russia is its third-largest shareholder behind China and India.
Former Reserve Bank of India governor Urjit Patel is the vice president for investment operations of the Beijing-headquartered AIIB. The bank is headed by former Chinese vice-minister for finance Jin Liqun.
"Our Bank is actively monitoring the situation and assessing its impact on AIIB's operations and our members' economies" as the Ukraine war unfolded, a press release posted on the bank's website said.
"We, the management, will do our utmost to safeguard the financial integrity of AIIB, against the backdrop of the evolving economic and financial situation," it said.
"Under these circumstances, and in the best interests of the Bank, Management has decided that all activities relating to Russia and Belarus are on hold and under review," the release said.
The bank has financed several projects in Russia and Belarus.
Explaining its decision to put the projects in Russia on hold, the AIIB said it is a multilateral organisation created by an international treaty, and adherence to international law lies at the very core of our institution".
"AIIB Management believes that multilateralism provides the best framework for countries to cooperate in dealing with common challenges and supporting development," it said.
"As the war in Ukraine unfolds, AIIB extends its thoughts and sympathy to everyone affected. Our hearts go out to all who are suffering," it said.
"AIIB stands ready to extend financing flexibly and quickly and support members who have been adversely impacted by the war, directly or indirectly," the release said.
"Economic spillover from commodity price shocks, financial market volatility and other factors may adversely impact our members' economic situation. We will work closely with our partner multilateral organisations to provide any needed support expeditiously," it said.
On Wednesday, the World Bank announced that it will stop all its programmes in Russia and Belarus with "immediate effect" in response to Moscow's military operations in Ukraine and "hostilities" against the people of the war-torn country.
A large number of countries, organisations and businesses are severing ties and have imposed sanctions on Russia over the country's invasion of Ukraine, and with Belarus for its support and cooperation with Moscow.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.